8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 25, 2026·SEC
Teladoc Health, Inc.(TDOC)Earnings, Financials & Key Ratios
TDOC•NYSE
Price updated Jun 19, 2026
AboutTeladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.Show more
- Revenue$2.53B-1.5%
- EBITDA$100M+112.8%
- Net Income-$200M+80.0%
- EPS (Diluted)-1.14+80.6%
- Gross Margin69.5%-1.8%
- EBITDA Margin3.96%+113.0%
- Operating Margin-10.39%+73.8%
- Net Margin-7.92%+79.7%
- ROE-13.93%+73.5%
TDOC Key Insights
Teladoc Health, Inc. (TDOC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 16.2%
- ✓Momentum leader: RS Rating 85 (top 15%)
- ✓Strong 5Y sales CAGR of 18.3%
- ✓Trading at only 1.0x book value
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TDOC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TDOC Price & Volume
Teladoc Health, Inc. (TDOC) stock price & volume — 10-year historical chart
Loading chart...
TDOC Growth Metrics
Teladoc Health, Inc. (TDOC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years41.73%
5 Years18.26%
3 Years1.68%
TTM-1.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM83.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.61%
Return on Capital
10 Years-23.1%
5 Years-34.9%
3 Years-15.72%
Last Year-9.98%
TDOC Recent Earnings
Teladoc Health, Inc. (TDOC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.36-5.5%
$0.34
Rev
$614M+0.5%
$611M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.14+26.3%
$0.19
Rev
$642M+1.1%
$635M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.21+19.2%
$0.26
Rev
$626M-1.4%
$635M
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.19+29.6%
$0.27
Rev
$632M+0.7%
$628M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.36vs $0.34-5.5% | $614Mvs $611M+0.5% |
| Q1 2026 | Feb 25, 2026 | $0.14vs $0.19+26.3% | $642Mvs $635M+1.1% |
| Q4 2025 | Oct 29, 2025 | $0.21vs $0.26+19.2% | $626Mvs $635M-1.4% |
| Q3 2025 | Jul 29, 2025 | $0.19vs $0.27+29.6% | $632Mvs $628M+0.7% |
Based on last 12 quarters of dataView full earnings history →
TDOC Peer Comparison
Teladoc Health, Inc. (TDOC) competitors in Virtual Care and Digital Programs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AMWL | 140.85M | 8.43 | -1.41 | -1.98% | -48.16% | -33.48% | 0.02 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 DOCS | 3.83B | 20.46 | 20.88 | 13.05% | 30.4% | 19.36% | 0.01 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 OMCL | 1.78B | 39.05 | 881.49 | 6.53% | 1.67% | 1.64% | 0.17 | |
 GDRX | 922.03M | 2.66 | 31.18 | 0.57% | 3.74% | 4.75% | 0.10 | |
 TALK | 872.74M | 5.21 | 130.25 | 22% | 0.49% | 1.03% | ||
 OPRX | 93.45M | 4.98 | 18.44 | 18.78% | 6.37% | 5.47% | 0.20 |
Compare TDOC vs Peers
Teladoc Health, Inc. (TDOC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TDOC Income Statement
Teladoc Health, Inc. (TDOC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 233.28M | 417.91M | 553.31M | 1.09B | 2.03B | 2.41B | 2.6B | 2.57B | 2.53B | 2.51B |
Revenue Growth % | 89.42% | 79.14% | 32.4% | 97.71% | 85.81% | 18.41% | 8.13% | -1.26% | -1.54% | -1.5% |
Cost of Goods Sold | 61.62M | 128.74M | 184.47M | 390.83M | 650.26M | 743.99M | 760.03M | 751.27M | 771.59M | 864.58M |
COGS % of Revenue | 26.42% | 30.8% | 33.34% | 35.73% | 31.99% | 30.91% | 29.2% | 29.24% | 30.5% | - |
Gross Profit | 171.66M▲ 0% | 289.17M▲ 68.5% | 368.84M▲ 27.6% | 703.13M▲ 90.6% | 1.38B▲ 96.6% | 1.66B▲ 20.3% | 1.84B▲ 10.8% | 1.82B▼ 1.3% | 1.76B▼ 3.3% | 1.65B▲ 0% |
Gross Margin % | 73.58% | 69.2% | 66.66% | 64.27% | 68.01% | 69.09% | 70.8% | 70.76% | 69.5% | 65.62% |
Gross Profit Growth % | 88.25% | 68.46% | 27.55% | 90.63% | 96.61% | 20.28% | 10.8% | -1.31% | -3.3% | - |
Operating Expenses | 247.05M | 360.03M | 449.28M | 1.21B | 1.65B | 15.32B | 2.09B | 2.84B | 2.02B | 1.84B |
OpEx % of Revenue | 105.9% | 86.15% | 81.2% | 110.57% | 81.08% | 636.36% | 80.35% | 110.49% | 79.9% | - |
Selling, General & Admin | 180.3M | 265.16M | 339.07M | 886.88M | 1.11B | 1.3B | 1.37B | 1.35B | 1.09B | 1.06B |
SG&A % of Revenue | 77.29% | 63.45% | 61.28% | 81.07% | 54.38% | 54.04% | 52.54% | 52.39% | 42.9% | - |
Research & Development | 34.46M | 54.37M | 64.64M | 164.94M | 311.88M | 333.63M | 348.52M | 307.27M | 277.92M | 320.12M |
R&D % of Revenue | 14.77% | 13.01% | 11.68% | 15.08% | 15.34% | 13.86% | 13.39% | 11.96% | 10.99% | - |
Other Operating Expenses | 32.29M | 40.49M | 45.57M | 157.73M | 230.88M | 13.68B | 375.12M | 1.19B | 658.15M | 3M |
Operating Income | -75.39M▲ 0% | -70.85M▲ 6.0% | -80.44M▼ 13.5% | -506.42M▼ 529.5% | -265.63M▲ 47.5% | -13.65B▼ 5039.9% | -248.55M▲ 98.2% | -1.02B▼ 310.7% | -262.95M▲ 74.2% | -191.07M▲ 0% |
Operating Margin % | -32.32% | -16.95% | -14.54% | -46.29% | -13.07% | -567.27% | -9.55% | -39.73% | -10.39% | -7.6% |
Operating Income Growth % | -20.31% | 6.02% | -13.53% | -529.55% | 47.55% | -5039.92% | 98.18% | -310.73% | 74.24% | - |
EBITDA | -56.3M | -35.25M | -41.49M | -442.73M | -58.06M | -13.44B | 5.56M | -780.38M | 100.17M | 42.11M |
EBITDA Margin % | -24.13% | -8.44% | -7.5% | -40.47% | -2.86% | -558.54% | 0.21% | -30.37% | 3.96% | 1.67% |
EBITDA Growth % | -3.5% | 37.38% | -17.7% | -967.07% | 86.89% | -23054.52% | 100.04% | -14133% | 112.84% | 105.04% |
D&A (Non-Cash Add-back) | 19.09M | 35.6M | 38.95M | 63.69M | 207.57M | 209.93M | 254.11M | 240.51M | 363.12M | 233.19M |
EBIT | -62.2M | -65.96M | -73.82M | -418.19M | -238.99M | -217.47M | -210.5M | -208.79M | -215.82M | -169.13M |
Net Interest Income | -17.49M | -26.11M | -29.36M | -59.95M | -80.36M | -9.27M | 24.5M | 33.27M | 17.06M | 88.32M |
Interest Income | 0 | 0 | 0 | 0 | 776K | 12.67M | 46.78M | 57.07M | 36.77M | 107.64M |
Interest Expense | 17.49M | 26.11M | 29.36M | 59.95M | 81.14M | 21.94M | 22.28M | 23.8M | 19.71M | 19.32M |
Other Income/Expense | -31.61M | -26.11M | -29.01M | -69.57M | -119.03M | -10.13M | 28.95M | 27.23M | 27.43M | 5.97M |
Pretax Income | -107.01M▲ 0% | -96.97M▲ 9.4% | -109.45M▼ 12.9% | -575.99M▼ 426.2% | -384.66M▲ 33.2% | -13.66B▼ 3452.1% | -219.61M▲ 98.4% | -993.65M▼ 352.5% | -235.53M▲ 76.3% | -185.1M▲ 0% |
Pretax Margin % | -45.87% | -23.2% | -19.78% | -52.65% | -18.92% | -567.69% | -8.44% | -38.67% | -9.31% | -7.36% |
Income Tax | -225K | 118K | -10.59M | -90.86M | 44.14M | -3.81M | 760K | 7.59M | -35.21M | -13.96M |
Effective Tax Rate % | 0.21% | -0.12% | 9.68% | 15.77% | -11.47% | 0.03% | -0.35% | -0.76% | 14.95% | 7.54% |
Net Income | -106.78M▲ 0% | -97.08M▲ 9.1% | -98.86M▼ 1.8% | -485.14M▼ 390.7% | -428.79M▲ 11.6% | -13.66B▼ 3085.6% | -220.37M▲ 98.4% | -1B▼ 354.4% | -200.32M▲ 80.0% | -171.15M▲ 0% |
Net Margin % | -45.77% | -23.23% | -17.87% | -44.35% | -21.09% | -567.53% | -8.47% | -38.97% | -7.92% | -6.81% |
Net Income Growth % | -43.88% | 9.08% | -1.83% | -390.71% | 11.61% | -3085.58% | 98.39% | -354.35% | 79.99% | 83.09% |
Net Income (Continuing) | -106.78M | -97.08M | -98.86M | -485.14M | -428.79M | -13.66B | -220.37M | -1B | -200.32M | -171.15M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.93▲ 0% | -1.47▲ 23.8% | -1.38▲ 6.1% | -5.36▼ 288.4% | -2.73▲ 49.1% | -84.60▼ 2998.9% | -1.34▲ 98.4% | -5.87▼ 338.1% | -1.14▲ 80.6% | -0.96▲ 0% |
EPS Growth % | -10.29% | 23.83% | 6.12% | -288.41% | 49.07% | -2998.9% | 98.42% | -338.06% | 80.58% | 83.61% |
EPS (Basic) | -1.93 | -1.47 | -1.38 | -5.36 | -2.73 | -84.60 | -1.36 | -5.87 | -1.14 | - |
Diluted Shares Outstanding | 55.43M | 65.84M | 71.84M | 90.51M | 156.94M | 161.46M | 164.58M | 170.56M | 176.22M | 179.12M |
Basic Shares Outstanding | 55.43M | 65.84M | 71.84M | 90.51M | 156.94M | 161.46M | 162.17M | 170.56M | 176.22M | 179.12M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TDOC Balance Sheet
Teladoc Health, Inc. (TDOC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 156.24M | 532.74M | 588M | 1.06B | 1.23B | 1.29B | 1.49B | 1.66B | 1.09B | 1.13B |
Cash & Short-Term Investments | 122.31M | 478.53M | 517.06M | 786.57M | 896.02M | 918.18M | 1.12B | 1.3B | 781.08M | 750.74M |
Cash Only | 42.82M | 423.99M | 514.35M | 733.32M | 893.48M | 918.18M | 1.12B | 1.3B | 781.08M | 750.74M |
Short-Term Investments | 79.49M | 54.55M | 2.71M | 53.24M | 2.54M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 27.09M | 43.57M | 56.95M | 169.28M | 190.12M | 235.65M | 230.06M | 223.96M | 201.66M | 213.63M |
Days Sales Outstanding | 42.39 | 38.05 | 37.57 | 56.48 | 34.14 | 35.74 | 32.27 | 31.81 | 29.09 | 31.53 |
Inventory | 0 | 0 | 0 | 56.5M | 73.08M | 56.34M | 29.51M | 38.14M | 38.2M | 31.56M |
Days Inventory Outstanding | - | - | - | 52.76 | 41.02 | 27.64 | 14.17 | 18.53 | 18.07 | 15.6 |
Other Current Assets | 6.84M | 10.63M | 0 | 0 | 27.96M | 12.1M | 40.15M | 36.02M | 2.07M | 136.42M |
Total Non-Current Assets | 668.15M | 996.14M | 1.01B | 16.7B | 16.51B | 3.42B | 2.9B | 1.85B | 2.01B | 1.67B |
Property, Plant & Equipment | 8.96M | 10.15M | 36.75M | 75.2M | 74.01M | 71.47M | 72.09M | 56.58M | 53.09M | 50.51M |
Fixed Asset Turnover | 26.03x | 41.18x | 15.06x | 14.55x | 27.46x | 33.68x | 36.10x | 45.42x | 47.65x | 46.55x |
Goodwill | 498.52M | 737.2M | 746.08M | 14.58B | 14.5B | 1.07B | 1.07B | 283.19M | 283.19M | 283.19M |
Intangible Assets | 159.81M | 247.39M | 225.45M | 2.02B | 1.91B | 1.84B | 1.68B | 1.43B | 1.3B | 1.24B |
Long-Term Investments | 49.4M | 94.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 858K | 1.4M | 6.54M | 18.36M | 20.7M | 78.5M | 80.26M | 81.49M | 137.62M | 106.04M |
Total Assets | 824.39M▲ 0% | 1.53B▲ 85.5% | 1.6B▲ 4.8% | 17.76B▲ 1007.7% | 17.73B▼ 0.1% | 4.7B▼ 73.5% | 4.39B▼ 6.6% | 3.52B▼ 19.9% | 3.1B▼ 11.8% | 2.81B▲ 0% |
Asset Turnover | 0.28x | 0.27x | 0.35x | 0.06x | 0.11x | 0.51x | 0.59x | 0.73x | 0.82x | 0.86x |
Asset Growth % | 171.48% | 85.46% | 4.84% | 1007.75% | -0.12% | -73.49% | -6.56% | -19.94% | -11.82% | -66.61% |
Total Current Liabilities | 40.33M | 62.44M | 90.18M | 332.65M | 331.01M | 399.77M | 420.62M | 941.53M | 404.74M | 404.87M |
Accounts Payable | 3.88M | 7.77M | 9.07M | 46.03M | 47.26M | 47.69M | 43.64M | 33.13M | 47.97M | 45.2M |
Days Payables Outstanding | 23.01 | 22.03 | 17.96 | 42.99 | 26.53 | 23.4 | 20.96 | 16.1 | 22.69 | 21.09 |
Short-Term Debt | 0 | 0 | 0 | 42.56M | 0 | 13.59M | 0 | 550.72M | 11.04M | 0 |
Deferred Revenue (Current) | 4.11M | 7.65M | 12.46M | 52.36M | 75.57M | 101.83M | 95.66M | 79.3M | 62.3M | 272.86M |
Other Current Liabilities | 12.05M | 16.54M | 39.26M | 128.92M | 132.21M | 151.28M | 167.26M | 69.33M | 187.17M | 233.29M |
Current Ratio | 3.87x | 8.53x | 6.52x | 3.19x | 3.70x | 3.22x | 3.54x | 1.77x | 2.69x | 2.80x |
Quick Ratio | 3.87x | 8.53x | 6.52x | 3.02x | 3.48x | 3.07x | 3.47x | 1.73x | 2.59x | 2.72x |
Cash Conversion Cycle | - | - | - | 66.26 | 48.63 | 39.98 | 25.48 | 34.25 | 24.47 | 26.04 |
Total Non-Current Liabilities | 225.16M | 453.32M | 498.62M | 1.54B | 1.36B | 1.99B | 1.65B | 1.08B | 1.31B | 1.07B |
Long-Term Debt | 207.37M | 414.68M | 440.41M | 1.38B | 1.23B | 1.54B | 1.54B | 991.42M | 994.92M | 995.81M |
Capital Lease Obligations | 0 | 0 | 24.99M | 43.14M | 41.77M | 38.04M | 42.84M | 32.13M | 34.2M | 135.79M |
Deferred Tax Liabilities | 12.91M | 32.44M | 21.68M | 102.1M | 75.78M | 406.54M | 49.45M | 49.85M | 271.44M | 363.06M |
Other Non-Current Liabilities | 17.79M | 6.19M | 9.24M | 11.54M | 10.78M | 1.62M | 1.08M | 720K | 643K | 551K |
Total Liabilities | 265.49M | 515.76M | 588.8M | 1.87B | 1.69B | 2.39B | 2.07B | 2.03B | 1.72B | 1.47B |
Total Debt | 207.37M | 414.68M | 470.49M | 1.48B | 1.28B | 1.59B | 1.59B | 1.58B | 1.04B | 1.03B |
Net Debt | 164.55M | -9.31M | -43.86M | 743.41M | 386.65M | 668.74M | 468.6M | 286.29M | 259.08M | 276.81M |
Debt / Equity | 0.37x | 0.41x | 0.46x | 0.09x | 0.08x | 0.69x | 0.68x | 1.06x | 0.75x | 0.77x |
Debt / EBITDA | - | - | - | - | - | - | 286.33x | - | 10.38x | 24.40x |
Net Debt / EBITDA | - | - | - | - | - | - | 84.27x | - | 2.59x | 6.57x |
Interest Coverage | -3.56x | -2.53x | -2.51x | -6.98x | -2.95x | -9.91x | -9.45x | -8.77x | -10.95x | -8.76x |
Total Equity | 558.9M▲ 0% | 1.01B▲ 81.3% | 1.01B▲ 0.1% | 15.88B▲ 1466.4% | 16.05B▲ 1.0% | 2.31B▼ 85.6% | 2.33B▲ 0.8% | 1.49B▼ 35.9% | 1.39B▼ 7.1% | 1.34B▲ 0% |
Equity Growth % | 142.09% | 81.27% | 0.09% | 1466.41% | 1.02% | -85.62% | 0.79% | -35.9% | -7.07% | -26.41% |
Book Value per Share | 10.08 | 15.39 | 14.11 | 175.49 | 102.24 | 14.29 | 14.13 | 8.74 | 7.86 | 7.46 |
Total Shareholders' Equity | 558.9M | 1.01B | 1.01B | 15.88B | 16.05B | 2.31B | 2.33B | 1.49B | 1.39B | 1.34B |
Common Stock | 61K | 70K | 73K | 150K | 160K | 163K | 167K | 173K | 178K | 180K |
Retained Earnings | -311.58M | -408.66M | -507.52M | -992.66M | -1.42B | -15.01B | -15.23B | -16.23B | -16.43B | -16.49B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 4.09M | -13.07M | -17.24M | 18.52M | -6.29M | -42.78M | -36.99M | -38.39M | -34.73M | -35.42M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TDOC Cash Flow Statement
Teladoc Health, Inc. (TDOC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -34.44M | -4.86M | 29.87M | -53.51M | 193.99M | 189.29M | 350.02M | 293.68M | 294.36M | 287.95M |
Operating CF Margin % | -14.76% | -1.16% | 5.4% | -4.89% | 9.54% | 7.86% | 13.45% | 11.43% | 11.63% | - |
Operating CF Growth % | 33.51% | 85.89% | 714.59% | -279.15% | 462.52% | -2.42% | 84.91% | -16.1% | 0.23% | -44.88% |
Net Income | -106.78M | -97.08M | -98.86M | -485.14M | -428.79M | -13.66B | -220.37M | -1B | -200.32M | -171.15M |
Depreciation & Amortization | 19.09M | 35.6M | 44.95M | 78.09M | 219.62M | 270.64M | 348.72M | 382.84M | 363.12M | 370.85M |
Stock-Based Compensation | 30.6M | 43.77M | 66.7M | 475.53M | 0 | 0 | 201.55M | 145.95M | 80.41M | 69.86M |
Deferred Taxes | -306K | -2.25M | -10.87M | -90.16M | 41.8M | -7.84M | -1.9M | -1.15M | -41.41M | -15.6M |
Other Non-Cash Items | 22.23M | 16.23M | 29.35M | 58.65M | 411.69M | 13.65B | 10.38M | 803.59M | 91.48M | 28.06M |
Working Capital Changes | 720K | -1.13M | -1.4M | -90.48M | -50.32M | -60.97M | 11.64M | -36.31M | 1.07M | 5.93M |
Change in Receivables | -3.66M | -10.93M | -15.88M | -21.09M | -17.51M | -61.64M | -10.25M | -375K | 25.13M | 19.4M |
Change in Inventory | -923K | 1.71M | 0 | -24.73M | -19.49M | 14.8M | 24.09M | -9.75M | 399K | 5.2M |
Change in Payables | 1.53M | -391K | 905K | -88M | 1.19M | 1.88M | -4.18M | -10.37M | 11.45M | -8.01M |
Cash from Investing | -448.38M | -257.5M | 25.01M | -590.98M | -72.98M | -167.74M | -156.35M | -124.05M | -266M | -179.26M |
Capital Expenditures | -5.51M | -8.41M | -3.51M | -26.04M | -63.93M | -172.76M | -156.35M | -10.79M | -8.89M | -36.87M |
CapEx % of Revenue | 2.36% | 2.01% | 0.63% | 2.38% | 3.15% | 7.18% | 6.01% | 0.42% | 0.35% | 1.47% |
Acquisitions | -379.36M | -282.44M | -11.19M | -567.43M | -78.66M | 0 | 0 | 0 | -81.9M | -17.3M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -66.39M | 5.53M | -7.39M | 0 | 8.71M | 2.51M | 1K | -113.26M | -175.95M | -124.34M |
Cash from Financing | 475.43M | 645.61M | 35.09M | 859.14M | 40.95M | 6.5M | 10.85M | 8.31M | -551.65M | -554.87M |
Debt Issued (Net) | 203.96M | 279.16M | 0 | 761.85M | -914K | -3.15M | 0 | 0 | -550.63M | -550.63M |
Equity Issued (Net) | 258.55M | 330.84M | 0 | 0 | 42.59M | 12.38M | 0 | 8.31M | 3.08M | 2.2M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 12.92M | 35.61M | 35.09M | 97.29M | -730K | -2.74M | 10.85M | -2K | -4.11M | -6.44M |
Net Change in Cash | -7.2M▲ 0% | 381.17M▲ 5395.5% | 90.36M▼ 76.3% | 218.97M▲ 142.3% | 160.16M▼ 26.9% | 24.7M▼ 84.6% | 205.49M▲ 731.9% | 174.65M▼ 15.0% | -517.24M▼ 396.2% | -442.59M▲ 0% |
Free Cash Flow | -39.96M▲ 0% | -13.27M▲ 66.8% | 18.97M▲ 243.0% | -79.55M▼ 519.4% | 185.46M▲ 333.1% | 172.81M▼ 6.8% | 193.67M▲ 12.1% | 282.89M▲ 46.1% | 285.46M▲ 0.9% | 251.09M▲ 0% |
FCF Margin % | -17.13% | -3.17% | 3.43% | -7.27% | 9.12% | 7.18% | 7.44% | 11.01% | 11.28% | 9.99% |
FCF Growth % | 27.63% | 66.8% | 242.98% | -519.38% | 333.12% | -6.82% | 12.07% | 46.07% | 0.91% | 21.66% |
FCF per Share | -0.72 | -0.20 | 0.26 | -0.88 | 1.18 | 1.07 | 1.18 | 1.66 | 1.62 | 1.40 |
FCF Conversion (FCF/Net Income) | 0.32x | 0.05x | -0.30x | 0.11x | -0.45x | -0.01x | -1.59x | -0.29x | -1.47x | -1.47x |
Interest Paid | 9.45M | 10.3M | 12.22M | 14.89M | 0 | 0 | 17.42M | 17.32M | 0 | 8.66M |
Taxes Paid | 137K | 441K | 1.31M | 1.32M | 0 | 0 | 7.24M | 8.95M | 0 | 5.44M |
TDOC Key Ratios
Teladoc Health, Inc. (TDOC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -27.04% | -12.35% | -9.75% | -5.74% | -2.69% | -148.85% | -9.51% | -52.46% | -13.93% | -12.37% |
Return on Invested Capital (ROIC) | -11.92% | -6.15% | -6.11% | -4.32% | -1.21% | -105.52% | -6.46% | -33.49% | -11.53% | -8.5% |
Gross Margin | 73.58% | 69.2% | 66.66% | 64.27% | 68.01% | 69.09% | 70.8% | 70.76% | 69.5% | 65.62% |
Net Margin | -45.77% | -23.23% | -17.87% | -44.35% | -21.09% | -567.53% | -8.47% | -38.97% | -7.92% | -6.81% |
Debt / Equity | 0.37x | 0.41x | 0.46x | 0.09x | 0.08x | 0.69x | 0.68x | 1.06x | 0.75x | 0.77x |
Interest Coverage | -3.56x | -2.53x | -2.51x | -6.98x | -2.95x | -9.91x | -9.45x | -8.77x | -10.95x | -8.76x |
FCF Conversion | 0.32x | 0.05x | -0.30x | 0.11x | -0.45x | -0.01x | -1.59x | -0.29x | -1.47x | -1.47x |
Revenue Growth | 89.42% | 79.14% | 32.4% | 97.71% | 85.81% | 18.41% | 8.13% | -1.26% | -1.54% | -1.5% |
Related:TDOC Dividend History·TDOC Revenue History·TDOC Price History·TDOC P/E History·TDOC Financial Ratios·TDOC Institutional Holders
TDOC SEC Filings & Documents
Teladoc Health, Inc. (TDOC) SEC filings — annual & quarterly reports (10-K, 10-Q)
TDOC Frequently Asked Questions
Teladoc Health, Inc. (TDOC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Teladoc Health, Inc. (TDOC) reported $2.51B in revenue for fiscal year 2025. This represents a 12532% increase from $19.9M in 2013.
Teladoc Health, Inc. (TDOC) saw revenue decline by 1.5% over the past year.
Teladoc Health, Inc. (TDOC) reported a net loss of $171.1M for fiscal year 2025.
Dividend & Returns
Teladoc Health, Inc. (TDOC) has a return on equity (ROE) of -13.9%. Negative ROE indicates the company is unprofitable.
Teladoc Health, Inc. (TDOC) generated $251.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.